title: Neoadjuvant hormonal therapy plus surgery for prostate cancer. The MSKCC experience.
abstract: This article reviews the current status of neoadjuvant hormonal therapy (NHT) in the treatment of clinically localized prostate cancer. Although significant increases in the organ confined rate and similar marked decreases in the positive margin rate are found in patients receiving NHT, to date no difference in disease free survival rate, as determined by PSA values, can be shown. However, there is a suggestion (P = 10 ng/ ml when treated with NHT compared with controls. Given the prolonged natural history of prostate cancer, longer follow-up will be required before the value of NHT can be established.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
authors.forename: W R
authors.initials: WR
authors.lastname: Fair
authors.forename: H I
authors.initials: HI
authors.lastname: Scher
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D005544:Forecasting; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009360:Neoplastic Cells, Circulating; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000032:analysis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000601:surgery*; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen